lncRNA PCAT14 Is a Diagnostic Marker for Prostate Cancer and Is Associated with Immune Cell Infiltration

Table 1

Correlation between PCAT14 and clinical indicators of patients.

	Low expression of PCAT14	High expression of PCAT14
	249	250
T stage, (%)			0.005
T2	76 (15.4%)	113 (23%)
T3	160 (32.5%)	132 (26.8%)
T4	7 (1.4%)	4 (0.8%)
N stage, (%)			0.009
N0	169 (39.7%)	178 (41.8%)
N1	52 (12.2%)	27 (6.3%)
M stage, (%)			0.249
M0	230 (50.2%)	225 (49.1%)
M1	3 (0.7%)	0 (0%)
Primary therapy outcome, (%)			0.022
PD	16 (3.7%)	12 (2.7%)
SD	18 (4.1%)	11 (2.5%)
PR	27 (6.2%)	13 (3%)
CR	156 (35.6%)	185 (42.2%)
Race, (%)			0.195
Asian	9 (1.9%)	3 (0.6%)
Black or African American	30 (6.2%)	27 (5.6%)
White	204 (42.1%)	211 (43.6%)
Age, (%)			0.342
≤60	106 (21.2%)	118 (23.6%)
>60	143 (28.7%)	132 (26.5%)
Residual tumor, n (%)			<0.001
R0	133 (28.4%)	182 (38.9%)
R1	100 (21.4%)	48 (10.3%)
R2	1 (0.2%)	4 (0.9%)
PSA (ng/ml), (%)			0.347
<4	199 (45%)	216 (48.9%)
≥4	16 (3.6%)	11 (2.5%)
Gleason score, (%)			< 0.001
6	16 (3.2%)	30 (6%)
7	103 (20.6%)	144 (28.9%)
8	34 (6.8%)	30 (6%)
9	92 (18.4%)	46 (9.2%)
10	4 (0.8%)	0 (0%)
OS event, (%)			0.339
Alive	246 (49.3%)	243 (48.7%)
Dead	3 (0.6%)	7 (1.4%)
Age,			0.020
PSA (ng/ml),			0.179

PD: progressive disease; SD: stable disease; PR: partial response; CR: complete response; PSA: prostate-specific antigen; OS: overall survival.